Pharmaceuticals
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinic...
2021-02-04 21:00
5137
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb. 4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Ph...
2021-02-04 18:41
2024
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®)...
2021-02-03 23:45
5416
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
CHENGDU, China, Feb. 3, 2021 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept. The drug is an anti-VEGF fusion protein, approv...
2021-02-03 22:00
4330
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
2021-02-03 22:00
6641
Nippon Express (Thailand) Obtains GDP Certification for Domestic Transport Services
TOKYO, Feb. 2, 2021 /PRNewswire/ -- Nippon Express (Thailand) Co., Ltd. (hereinafter, "NE Thailand"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveTuesday, December 22, 2020, evidencing its compliance with stand...
2021-02-02 14:00
1370
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA
SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (...
2021-02-02 12:11
3916
DW Healthcare Partners Invests in Parnell
PARK CITY, Utah, Feb. 2, 2021 /PRNewswire/ -- DW Healthcare Partners ("DWHP") a healthcare-focused private equity firm, announced the completion of its investment in Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF) ("Parnell" or the "Company"). Founded over 50 years ago inAustralia, Parnell is a...
2021-02-02 08:23
3019
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
* Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial * Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy pot...
2021-02-01 14:00
3476
DWHP Announces Expiration And Final Results Of Its Cash Tender Offer For All Outstanding Ordinary Shares Of Parnell Pharmaceuticals Holdings Ltd.
PARK CITY, Utah, Jan. 30, 2021 /PRNewswire/ -- DW Healthcare Partners V, L.P. ("DWHP"), announced today the expiration and final results of its previously announced cash tender offer (the "Tender Offer") to purchase all of the outstanding ordinary shares (the "Tender Securities") of Parnell Phar...
2021-01-30 07:38
9255
Nippon Express Bangladesh Obtains GDP Certification for Air Cargo Import/Export Services
TOKYO, Jan. 29, 2021 /PRNewswire/ -- Nippon Express Bangladesh Ltd. (hereinafter, "NE Bangladesh"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveSunday, December 13, 2020, evidencing its compliance with standard...
2021-01-29 15:00
1549
Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA
SEOUL, South Korea, Jan. 28, 2021 /PRNewswire/ -- Immunoforge, the company specializing in the development of new drugs for rare musculoskeletal diseases (Representatives: An Seong-Min and Jang Gi-Ho), announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for t...
2021-01-28 22:00
1918
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO serv...
2021-01-27 08:26
6104
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerabili...
2021-01-26 05:05
3417
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...
2021-01-26 01:18
5828
China Biologic Announces Extraordinary General Meeting of Shareholders
BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...
2021-01-25 21:44
8971
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19
TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investi...
2021-01-22 12:00
1780
China Jo-Jo Drugstores Hosts the First Suppliers Conference in China
HANGZHOU, China, Jan. 21, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that the...
2021-01-21 21:30
6903
Jemincare initiates phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002
NANCHANG, China, Jan. 20, 2021 /PRNewswire/ -- On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002). Preclinical studies of JMB2002 including pharmacology and toxicity were ...
2021-01-20 13:53
1372
Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL
SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the Nati...
2021-01-19 19:30
3827
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8703
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5845
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5183